EVAR with No Complications in Octogenarians: Survival Rate Identical to that of Healthy Octogenarians

This analysis reports (for the first time in the literature) that after the endovascular aortic aneurysm repair (EVAR) in octogenarians, survival rate is the same as that of their healthy counterparts.  

Pacientes que no siguen nuestro consejo y sorpresivamente tienen menos eventos

This is true provided the procedure does not present complications. If any, mortality results twice as high in this group. 

Using propensity score, researchers compared octogenarians with identical comorbidities undergoing EVAR vs. others with no aortic aneurysm from the Rotterdam study.

Complications rate for this procedure resulted 27% (mainly cardiac, pulmonary and access complications). This represents twice as many complications than in younger patients, which emphasizes the importance of correct patient selection.


Read also: Another Scandal in Evidence-Based Medicine: Ambulatory BP Monitoring Questioned?


After uncomplicated EVAR, mortality results similar vs the control group in the Rotterdam trial (HR 1.09, CI 95% 0.68 to 1.77). However, should there be any complications, these figures would see a dramatic change (HR 1.93, CI 95% 1.06 to 3.54).

Conclusion

After uncomplicated EVAR in 80+ patients, survival rate is the same as their healthy contemporaries. 

Patient selection and perioperatory care should be carried out thoroughly. 

Original Title: Survival After Uncomplicated EVAR in Octogenarians is Similar to the General Population of Octogenarians Without an Abdominal Aortic Aneurysm.

Reference: Oscar L. Rueda-Ochoa et al. Eur J Vasc Endovasc Surg, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...